drugset
drugset / Trial / NCT05935085

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

NCT05935085 ↗

Phase 2 Terminated 201 enrolled AnaptysBio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Timeline

Start
2023-06-13
Primary completion
2024-10-16
Completion
2025-01-07

Outcome

Missed primary endpoint

Stopped: “ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis”

release “did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial” anaptysbio.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject ANB032 Unknown — Subcutaneous

Indications

atopic eczema